Two stocks in Healthcare
Lonza Group vs UCB: profit, growth, debt and price compared
UCB is stronger on 5 of 7 figures: profit margin, sales growth, debt, price for its expected profit and price trend. Lonza Group is stronger on 1: dividend.
Save both stocks to your watchlist and revisit their latest fundamentals.
| Lonza GroupLONN.SW | UCBUCB.BR | |
|---|---|---|
| Net margin | −1.6% | Stronger: 25.7% |
| Revenue growth, past year | +11.20% | Stronger: +22.50% |
| Debt to equity | 51.1% | Stronger: 30.8% |
| Forward P/E | 29.7× | Stronger: 19.1× |
| Dividend yield | Stronger: 0.75% | 0.51% |
| Analysts | Buy · 23 | Buy · 19 |
| From its 200-day average | +17.8% | Stronger: +19.9% |
Share price over the past year
- Lonza Group+24.6%
- UCB+20.8%
24 Nov 202518 Nov 2026
Lonza Group or UCB: which is stronger?
- UCB.BR
Which is more profitable?
UCB keeps more of each sale as profit: 25.7% against −1.6%.
- UCB.BR
Which is growing its sales faster?
UCB is growing its sales faster: +22.50% over the past year, against +11.20%.
- UCB.BR
Which has borrowed less?
UCB has borrowed less: its debt is 30.8% of what its shareholders own, against 51.1% for Lonza Group.
- UCB.BR
Which costs less for the profit it is expected to make?
UCB costs less for the profit it is expected to make: 19.1× its forward earnings, against 29.7×.
- LONN.SW
Which pays more in dividends?
Lonza Group pays more back in dividends for what a share costs: 0.75% a year, against 0.51%.
Which do analysts rate higher?
Analysts rate both the same: Buy.
- UCB.BR
Which is in the stronger price trend?
UCB's price is in the stronger trend: 19.9% above its 200-day average, against 17.8% above.
What each company does
LONN.SWLonza Group
Lonza Group AG, together with its subsidiaries, operates as a contract development and manufacturing organization for pharma and biotech companies in Europe, North and Central America, Latin America, Asia, Australia, and internationally.
Reports results on 27 January 2027
UCB.BRUCB
UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide.
Reports results on 25 February 2027
This comparison is just the starting point.
Discover opportunities, understand companies and compare investments in one place. See how StratDeck works
Keep researching
Where next
More comparisons
Free email
Up to speed in minutes, four times a week
Every Monday, know what moved AI stocks and what to watch next. Every Wednesday and Friday, find a stock worth a look and learn its story. Every Sunday, catch up on the market's week in two minutes.
Early access
Become a StratDeck founding user
Use StratDeck, tell us what's missing, and help decide what we build next.
100 founding places. Founding users get their first month free, then half price for life: £2.99 a month or £30 a year.